company background image
RGS

RegeneusASX:RGS Stock Report

Market Cap

AU$23.3m

7D

2.7%

1Y

-49.3%

Updated

16 Oct, 2021

Data

Company Financials
RGS fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health4/6
Dividends0/6

RGS Overview

Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Regeneus
Historical stock prices
Current Share PriceAU$0.076
52 Week HighAU$0.069
52 Week LowAU$0.15
Beta0.046
1 Month Change2.01%
3 Month Change2.70%
1 Year Change-49.33%
3 Year Change-61.03%
5 Year Change-50.97%
Change since IPO-71.85%

Recent News & Updates

Shareholder Returns

RGSAU BiotechsAU Market
7D2.7%2.3%0.9%
1Y-49.3%1.5%20.2%

Return vs Industry: RGS underperformed the Australian Biotechs industry which returned 1.5% over the past year.

Return vs Market: RGS underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is RGS's price volatile compared to industry and market?
RGS volatility
RGS Beta0.046
Industry Beta1.61
Market Beta1

Stable Share Price: RGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: RGS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aKarolis Rosickashttps://regeneus.com.au

Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing.

Regeneus Fundamentals Summary

How do Regeneus's earnings and revenue compare to its market cap?
RGS fundamental statistics
Market CapAU$23.29m
Earnings (TTM)AU$2.15m
Revenue (TTM)AU$7.96m

10.8x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGS income statement (TTM)
RevenueAU$7.96m
Cost of RevenueAU$0
Gross ProfitAU$7.96m
ExpensesAU$5.80m
EarningsAU$2.15m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.007
Gross Margin100.00%
Net Profit Margin27.06%
Debt/Equity Ratio63.4%

How did RGS perform over the long term?

See historical performance and comparison

Valuation

Is Regeneus undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RGS (A$0.08) is trading below our estimate of fair value (A$1.32)

Significantly Below Fair Value: RGS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RGS is good value based on its PE Ratio (10.8x) compared to the Global Biotechs industry average (34.4x).

PE vs Market: RGS is good value based on its PE Ratio (10.8x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RGS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RGS is overvalued based on its PB Ratio (9.7x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Regeneus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regeneus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Regeneus performed over the past 5 years?

5.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RGS has high quality earnings.

Growing Profit Margin: RGS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RGS has become profitable over the past 5 years, growing earnings by 5.6% per year.

Accelerating Growth: RGS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RGS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (45.9%).


Return on Equity

High ROE: RGS's Return on Equity (89.3%) is considered outstanding.


Financial Health

How is Regeneus's financial position?


Financial Position Analysis

Short Term Liabilities: RGS's short term assets (A$5.2M) exceed its short term liabilities (A$1.3M).

Long Term Liabilities: RGS's short term assets (A$5.2M) exceed its long term liabilities (A$1.6M).


Debt to Equity History and Analysis

Debt Level: RGS's debt to equity ratio (63.4%) is considered high.

Reducing Debt: Insufficient data to determine if RGS's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: RGS's debt is well covered by operating cash flow (158.3%).

Interest Coverage: RGS's interest payments on its debt are well covered by EBIT (32.4x coverage).


Balance Sheet


Dividend

What is Regeneus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RGS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Karolis Rosickas

0.92

Tenure

Mr. Karolis Rosickas serves as Chief Executive Officer at Regeneus Ltd since November 2, 2020. He is an experienced executive and healthcare entrepreneur with business experience in healthcare, technology...


Leadership Team

Experienced Management: RGS's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: RGS's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.


Top Shareholders

Company Information

Regeneus Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Regeneus Ltd
  • Ticker: RGS
  • Exchange: ASX
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$23.289m
  • Shares outstanding: 306.44m
  • Website: https://regeneus.com.au

Location

  • Regeneus Ltd
  • 2 Paddington Street
  • Paddington
  • New South Wales
  • 2021
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.